Overall rank by patents
#13,803
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Yangtze River Pharmaceutical Group Co., Ltd.
USPTO PatentsView assignee record - 22 granted patents across 6 technology areas, active 2018–2021. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
22
Total patents granted
6
CPC technology areas
15.3
Avg claims per patent
+114%
5-year filing velocity
The verdict
Yangtze holds 22 US patents across 6 technology areas, rank #13,803 of 50,000 tracked assignees.
- #13,803
- of 50,000 US assignees by volume
- Top 72%
- by Innovation Score (28.7/100)
- 15.3
- avg claims per patent
- +114%
- filing velocity, last 5 yrs
Portfolio overview
YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. has been granted 22 US utility patents between 2018 and 2021, placing YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. at rank #13,803 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.3 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 28.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 15 grants, compared with 7 in the 2015–2019 window, a +114% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.'s 15.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. against peers pursuing similar technology classes.
How does YANGTZE compare?
Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Yangtze River Pha… ◀ 22
YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
22 patents
What this shows YANGTZE holds 22 patents, placing it at rank #13,803 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
YANGTZE's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
29 Top 72% higher than 28% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2018–2021
Grants by year
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 5 | 22.7% |
| 2019 | 2 | 9.1% |
| 2020 | 7 | 31.8% |
| 2021 | 8 | 36.4% |
Which technologies does YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. patent most?
Top 6 of 6 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Accelerating
Frequently Asked Questions
How many patents does YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. hold?
YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. holds 22 US granted patents filed between 2018 and 2021, spanning 6 technology areas.
What is YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.'s Innovation Score?
YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. has an Innovation Score of 28.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. focus on?
YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 21 patents. The company has filed patents in 6 CPC subclasses total.
Is YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.'s patent filing rate increasing or decreasing?
YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.'s recent filing velocity is +114% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.'s patents?
YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.'s patents average 15.3 claims each. This falls within the standard range, providing solid legal coverage.
How is the YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Guides to patent portfolio analysis
How to use this portfolio
Yangtze's 22 grants land it in the top 72% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Yangtze ranks #13,803 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
A61P technology
YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.'s primary CPC class, all holders and yearly trends
Top 50 patent holders
See where YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov
